Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hematology-Oncology Associates of Illinois
Chicago, Illinois, United States
- Northwestern University, Northwestern Medical Faculty Foundation
Chicago, Illinois, United States
- Midwest Center for Hematology/oncology
Joliet, Illinois, United States
- Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
Olympia Fields, Illinois, United States
- Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 May 2006
- Primary completion
- 10 Nov 2006
- Completion
- 5 Aug 2010
- Last update posted
- 6 Mar 2020
- Registered enrollment
- 30
- Registry id
- NCT00331630
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.